Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550094 | 1.00 | L3MBTL1 (0.74) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5634356 | 0.93 | L3MBTL1 (0.64) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL24607970 | 0.91 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29751053 | 0.91 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL28930005 | 0.88 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29641143 | 0.85 | L3MBTL1 (0.55) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8299867 | 0.82 | SMN1; SMN2 (0.57) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL16001308 | 0.81 | SMN1; SMN2 (0.53) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8304381 | 0.81 | ALDH1A1 (0.59) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL38662243 | 0.81 | SMN1; SMN2 (0.53) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-0846110-B1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2002-08-28 | — | — | EP | disclosed |
| US-5977135-A | Bicyclic heterocycles | ZENECA LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| EP-0733051-B1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| EP-0846110-A1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5723490-A | THF-containing sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-03-03 | — | — | US | disclosed |
| US-5602138-A | NKA affecting piperidyl heterobicyclic compounds | ZENECA LIMITED (GB) | 1997-02-11 | — | — | US | disclosed |
| WO-1996033184-A1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0733051-A1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015961-A1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | CDK2, CDK4, CCNI | L3MBTL1 2938/4885SMN1; SMN2 1848/4885NPC1 4195/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | L3MBTL1 2632/4885SMN1; SMN2 3712/4885NPC1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.